Open AccessOral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
Author(s) -
Oluwaseun FaladeNwulia,
Catalina SuarezCuervo,
David R. Nelson,
Michael Fried,
Jodi B Segal,
Mark Sulkowski
Publication year - 2017
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m16-2575
Subject(s) - medicine , ribavirin , adverse effect , discontinuation , regimen , hepatitis c , population , hepatitis c virus , sofosbuvir , cirrhosis , immunology , virus , environmental health
Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom